Abstract
A combination of carboplatin, vincristine, methotrexate and bleomycin (COMB) was given to 29 patients with locally advanced, metastatic or recurrent cervical carcinoma. A total of 85 cycles of chemotherapy were given, with half of the patients receiving greater than 3 cycles. Both the response rate (32.1%) and the median duration of response (30 weeks) were relatively disappointing. Renal toxicity was minimal, but one-third of our patients experienced severe (WHO grades 3 and 4) nausea and vomiting. This combination showed little advantage over carboplatin used as a single agent.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Carboplatin / administration & dosage*
-
Carboplatin / adverse effects
-
Carcinoma, Squamous Cell / drug therapy
-
Carcinoma, Squamous Cell / pathology
-
Drug Evaluation
-
Female
-
Humans
-
Leukopenia / chemically induced
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Middle Aged
-
Nausea / chemically induced
-
Remission Induction
-
Uterine Cervical Neoplasms / drug therapy*
-
Uterine Cervical Neoplasms / pathology
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
-
Vomiting / chemically induced
Substances
-
Bleomycin
-
Vincristine
-
Carboplatin
-
Methotrexate